Show simple item record

Recombinant human anti–transforming growth factor Β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

dc.contributor.authorDenton, Christopher P.en_US
dc.contributor.authorMerkel, Peter A.en_US
dc.contributor.authorFurst, Daniel E.en_US
dc.contributor.authorKhanna, Dineshen_US
dc.contributor.authorEmery, Paulen_US
dc.contributor.authorHsu, Vivien M.en_US
dc.contributor.authorSilliman, Nancyen_US
dc.contributor.authorStreisand, Jamesen_US
dc.contributor.authorPowell, Johnen_US
dc.contributor.authorÅkesson, Anitaen_US
dc.contributor.authorCoppock, Johnen_US
dc.contributor.authorHoogen, Frank van denen_US
dc.contributor.authorHerrick, Arianeen_US
dc.contributor.authorMayes, Maureen D.en_US
dc.contributor.authorVeale, Douglasen_US
dc.contributor.authorHaas, Joannaen_US
dc.contributor.authorLedbetter, Stephenen_US
dc.contributor.authorKorn, Joseph H.en_US
dc.contributor.authorBlack, Carol M.en_US
dc.contributor.authorSeibold, James R.en_US
dc.date.accessioned2007-09-20T18:07:00Z
dc.date.available2008-04-03T18:47:58Zen_US
dc.date.issued2007-01en_US
dc.identifier.citationDenton, Christopher P.; Merkel, Peter A.; Furst, Daniel E.; Khanna, Dinesh; Emery, Paul; Hsu, Vivien M.; Silliman, Nancy; Streisand, James; Powell, John; Åkesson, Anita; Coppock, John; Hoogen, Frank van den; Herrick, Ariane; Mayes, Maureen D.; Veale, Douglas; Haas, Joanna; Ledbetter, Stephen; Korn, Joseph H.; Black, Carol M.; Seibold, James R. (2007). "Recombinant human anti–transforming growth factor Β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192." Arthritis & Rheumatism 56(1): 323-333. <http://hdl.handle.net/2027.42/55924>en_US
dc.identifier.issn0004-3591en_US
dc.identifier.issn1529-0131en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/55924
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17195236&dopt=citationen_US
dc.description.abstractObjective To evaluate CAT-192, a recombinant human antibody that neutralizes transforming growth factor Β1 (TGFΒ1), in the treatment of early-stage diffuse cutaneous systemic sclerosis (dcSSc). Methods Patients with SSc duration of <18 months were randomly assigned to the placebo group or to 1 of 3 CAT-192 treatment groups: 10 mg/kg, 5 mg/kg, 0.5 mg/kg. Infusions were given on day 0 and weeks 6, 12, and 18. The primary objective of this study was to evaluate the safety, tolerability, and pharmacokinetics of CAT-192. Secondary outcomes included the modified Rodnan skin thickness score (MRSS), the Scleroderma Health Assessment Questionnaire, assessment of organ-based disease, serum levels of soluble interleukin-2 receptor, collagen propeptides (N propeptide of type I [PINP] and type III collagen), and tissue levels of messenger RNA for procollagens I and III and for TGFΒ1 and TGFΒ2. Results Forty-five patients were enrolled. There was significant morbidity and mortality, including 1 death in the group receiving 0.5 mg/kg of CAT-192 and 3 deaths in the group receiving 5 mg/kg of CAT-192. There were more adverse events and more serious adverse events in patients receiving CAT-192 than in those receiving placebo, although these events were not more frequent in the high-dose treatment group. The MRSS improved in all groups during the study, but there was no evidence of a treatment effect for CAT-192. Improvement in the MRSS correlated with the disease duration (r = −0.54, P = 0.0008). Changes in the PINP level from baseline correlated with changes in the MRSS (r = 0.37, P = 0.027). Conclusion We report the first evaluation of a systemically administered and repeatedly dosed anti-TGFΒ1 drug. In this pilot study, CAT-192, in doses up to 10 mg/kg, showed no evidence of efficacy. The utility of clinical and biochemical outcome measures and the feasibility of multicenter trials of early dcSSc were confirmed.en_US
dc.format.extent162817 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherLife and Medical Sciencesen_US
dc.titleRecombinant human anti–transforming growth factor Β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumRoyal Free Hospital, London, UK ; Boston University School of Medicine, Boston, Massachusetts ; University of California, Los Angeles ; Leeds University, Leeds, UK ; University of Medicine and Dentistry of New Jersey, New Brunswick ; Genzyme, Boston, Massachusetts ; Cambridge Antibody Technology, Cambridge, UK ; Lund University Hospital, Lund, Sweden ; Walsgrave Hospital, Coventry, UK ; University Hospital, Nijmegen, The Netherlands ; Hope Hospital, Salford, UK ; University of Texas Health Science Center at Houston ; St. Vincent's Hospital, Dublin, Ireland ; University of Michigan, Ann Arbor ; Dr. Korn is deceased.en_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arboren_US
dc.contributor.affiliationotherRoyal Free Hospital, London, UK ; Centre for Rheumatology, Royal Free and University College Medical School, Royal Free Hospital, Pond Street, London NW3 2QG, UKen_US
dc.contributor.affiliationotherBoston University School of Medicine, Boston, Massachusettsen_US
dc.contributor.affiliationotherUniversity of California, Los Angelesen_US
dc.contributor.affiliationotherUniversity of California, Los Angelesen_US
dc.contributor.affiliationotherLeeds University, Leeds, UKen_US
dc.contributor.affiliationotherUniversity of Medicine and Dentistry of New Jersey, New Brunswicken_US
dc.contributor.affiliationotherGenzyme, Boston, Massachusetts ; Drs. Silliman, Streisand, Haas, and Ledbetter own stock and/or hold stock options in Genzyme. Dr. Powell owns stock and/or holds stock options in Cambridge Antibody Technology. Dr. van den Hoogen has received consulting fees and/or honoraria (less than $10,000 each) from Abbott and Bristol-Myers Squibb. Dr. Mayes has received consulting fees or honoraria (less than $10,000 each) from Actelion, Encysive, and Novartis.en_US
dc.contributor.affiliationotherGenzyme, Boston, Massachusettsen_US
dc.contributor.affiliationotherCambridge Antibody Technology, Cambridge, UKen_US
dc.contributor.affiliationotherLund University Hospital, Lund, Swedenen_US
dc.contributor.affiliationotherWalsgrave Hospital, Coventry, UKen_US
dc.contributor.affiliationotherUniversity Hospital, Nijmegen, The Netherlandsen_US
dc.contributor.affiliationotherHope Hospital, Salford, UKen_US
dc.contributor.affiliationotherUniversity of Texas Health Science Center at Houstonen_US
dc.contributor.affiliationotherSt. Vincent's Hospital, Dublin, Irelanden_US
dc.contributor.affiliationotherGenzyme, Boston, Massachusettsen_US
dc.contributor.affiliationotherGenzyme, Boston, Massachusettsen_US
dc.contributor.affiliationotherRoyal Free Hospital, London, UKen_US
dc.identifier.pmid17195236en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/55924/1/22289_ftp.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1002/art.22289en_US
dc.identifier.sourceArthritis & Rheumatismen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.